Charles River Laboratories is down about 3.6% in the latest session as the market continues to price in a cautious 2026 setup: planned divestitures, ongoing restructuring, and investor sensitivity to demand visibility across CRO/preclinical services. The stock’s move fits a broader “risk re-rating” pattern seen since the company’s late-winter updates, where investors have treated portfolio changes and margin/volume uncertainty as a near-term overhang. (morningstar.com)

Recent company updates around divestitures put hard numbers on the business being sold and reinforced that reported growth comparisons will be affected by portfolio pruning. Separately, the company’s most recent annual results included significant impairment charges, which has kept the debate centered on quality of earnings, the pace of normalization in demand, and whether cost actions can offset a lower-growth top line. (morningstar.com)

Beyond the divestiture math, investors have been repeatedly confronted with restructuring-related headlines, including site actions and layoffs connected to footprint changes. That backdrop can amplify day-to-day volatility because any incremental negative signal—whether on utilization, bookings, or margin cadence—tends to be interpreted as evidence the recovery narrative is slipping. (fiercebiotech.com)